Bahija Jallal (file photo)
TCR pioneer Immunocore scores a first with a landmark PhIII snapshot on overall survival for a rare melanoma
Bahija Jallal’s crew at TCR pioneer Immunocore says they have nailed down a promising set of pivotal data for their lead drug in a frontline …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
